Barclays’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$362K Buy
+27,000
New +$402K ﹤0.01% 3640

Other funds holding CTNM

Barclays's CTNM Position: Q3 2026 in Review

Barclays reduced its Contineum Therapeutics (CTNM) stake by 74% in Q3 2026, selling an estimated $641K and leaving 15,166 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.

Barclays first reported a position in CTNM in Q2 2024 and has held it in 10 quarters since. The position peaked at $953K in Q2 2026. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Barclays held 15,166 shares of Contineum Therapeutics worth $204K as of Q3 2026.
  • Barclays sold 43,007 Contineum Therapeutics shares in Q3 2026, an estimated $641K.
  • Contineum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3964 holding.
  • Barclays first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Barclays's Contineum Therapeutics position peaked at $953K in Q2 2026.
  • 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.